GlassScriptPhysician profile
Daniel B Tavari
NPI 1942240213
$9,891.72
in general payments reported to CMS, 2019-2025
71 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,977 · 2020: $1,347 · 2021: $1,120 · 2022: $1,247 · 2023: $1,141 · 2024: $1,618 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,097 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,097.14 |
| Education | $104.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,026.30 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Amgen INC. | $1,608.83 | 2019-2025 | Evenity, Repatha, Prolia |
| Pfizer INC. | $483.66 | 2019-2025 | |
| Astellas Pharma US INC | $431.22 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $382.28 | 2019-2025 | |
| Allergan, INC. | $342.06 | 2019-2020 | |
| Abbott Laboratories | $331.86 | 2020-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $312.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $291.37 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $255.61 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $192.98 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $188.74 | 2019-2024 | Jardiance, Zepbound, Emgality |
| Novo Nordisk INC | $157.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $155.69 | 2019-2025 | Tymlos |
| Grifols USA, LLC | $149.56 | 2023-2025 | Prolastin-C Liquid |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tavari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.